Healthcare Industry 2020 - Facts and Figures for Baden-Württemberg - MEDTECH PHARMA BIOTECH - Gesundheitsindustrie BW

Healthcare Industry 2020 - Facts and Figures for Baden-Württemberg - MEDTECH PHARMA BIOTECH - Gesundheitsindustrie BW
Healthcare Industry 2020
  Facts and Figures for Baden-Württemberg

MEDTECH         PHARMA            BIOTECH
Healthcare Industry 2020 - Facts and Figures for Baden-Württemberg - MEDTECH PHARMA BIOTECH - Gesundheitsindustrie BW

            4    Foreword

            5    Baden-Württemberg – an outstanding location
                 for the Healthcare Industry

            12   Medical Technology Sector

            20   Pharmaceutical Industry and Biotechnology

                 21 Pharmaceutical industry
                 23 Medical biotechnology

            32   Research in Baden-Württemberg

            34   Company Foundation and Financing in

            36   Clusters and Networks

            38   Database and Methods

            39   Sources

            42   Imprint
Healthcare Industry 2020 - Facts and Figures for Baden-Württemberg - MEDTECH PHARMA BIOTECH - Gesundheitsindustrie BW
Foreword                                                                                                                   Baden-Württemberg –
                                                                                                                               an outstanding location
                                                   Prof. Dr. Ralf Kindervater,                                                 for the Healthcare
                                      CEO BIOPRO Baden-Württemberg GmbH
    What will the healthcare system of the future look like?     or smart implants. It has gained a prominent place in
    How can we meet the challenges of demographic develop-       the media and in the public eye due to the coronavirus
    ment, increasing cost pressure and the shortage of skilled   pandemic. The current, very positive perception should
    workers? What influence will digitalisation and artificial   be used to underline once again the importance of the
    intelligence have, and what space will they occupy? BIO-     Healthcare Industry and the healthcare sector in general.
    PRO Baden-Württemberg, which acts as a contact for the
    state’s Healthcare Industry – comprising medical technol-    The Healthcare Industry operates in a highly regulated
    ogy, pharmaceutical industry and biotechnology – is an       market that is increasingly coming under pressure from
    organisation dedicated to these exciting issues.             large non-industry (IT) companies and global compe-                                      Baden-Württemberg is a leading
                                                                 tition. At the same time, digital transformation, robot-                                 exporter and the most important
    The new Healthcare Industry 2020 - Facts and Figures for     ics and personalised medicine are set to revolutionise                                   location for the industrial healthcare
    Baden-Württemberg report once again proves the impor-        healthcare. Interdisciplinarity and networking among                                     sector in Germany1
    tance of these sectors that play a key role in the economy   all players are indispensable in this process. BIOPRO
    and employment. The Healthcare Industry drives inno-         Baden-Württemberg GmbH, as a wholly-owned affiliate                                5 University hospitals
    vation in healthcare, in areas such as the development       of the Baden-Württemberg government, makes a valua-
    of personalised therapies, companion diagnostics, bio-       ble contribution to this process.
                                                                                                                                                                        44 Research institutions und
    pharmaceuticals, novel cell therapies and biocompatible                                                                                                             		universities
                                                                                                                                            181   Companies founded in the
                                                                                                                                                  Healthcare Industry since 2010

    BIOPRO Baden-Württemberg GmbH
    BIOPRO Baden-Württemberg GmbH’s goals are to team players across industry boundaries, bring industry and sci-
                                                                                                                                                          1,104    Companies
                                                                                                                                                                   in the Healthcare Industry
    ence together, provide information on regulatory requirements and generate new impulses for the location. BIOPRO
    offers interdisciplinary topic analyses and trend-based market analyses, innovative event concepts, initiates collabora-
    tions between companies and research institutions, and offers start-up support and organises events on current-inter-
                                                                                                                                         17.8 Billion euros gross value added1
    est topics. BIOPRO is the contact partner for the Healthcare Industry in Baden-Württemberg.
                                                                                                                                                               95,750      Employees

                                                                                                                                  25.2 Billon euros turnover

4   | Healthcare industry 2020                                                                                                                                                                  Healthcare industry 2020 |   5
Healthcare Industry 2020 - Facts and Figures for Baden-Württemberg - MEDTECH PHARMA BIOTECH - Gesundheitsindustrie BW
The Healthcare Industry
             at a Glance

                                                                         What will the healthcare system of the fu-                   rials and supplies for manufacturing processes have not
                                                                         ture look like?                                              been available. As a result, the dependency of Europe-
                                                                         The development of a sustainable healthcare system that      an supply chains on the Asian market is being discussed
                                                                         is patient-oriented and guarantees high-quality treatment    within the industry and there is a debate about the ex-
                                                                         is a declared goal of current efforts to promote health      tent to which countermeasures can be taken. The medi-
                                                                         in Germany. The Healthcare Industry is working across        cal technology sector, which would have been pushed to
                                                                         industry boundaries on the holistic treatment of patients    its absolute limits due to the switch to the new Medical

                         MEDICAL TECHNOLOGY                              through the use of innovative technologies and the devel-    Device Regulation (MDR) in April 2020, was granted a
                                                                         opment of smart treatment concepts. In addition to new       one-year delay for the application of the regulation. The
    851                     52.092               13,79                   therapy concepts, smart technologies can use artificial      MDR will become fully applicable on 26th May 2021.This
  Companies                 Employees       Billion euros taxable        intelligence to optimise the search for active pharmaceu-    gives companies more time to develop additional com-
                                                                         tical ingredients, increase adherence to therapy, shorten    petence and implement the MDR-compliant certification
                     PHARMACEUTICAL INDUSTRY                             hospital stays and improve patient care through robotics.    process. The MDR Fast-Track Support BW programme,
                                                                                                                                      which is financed with funds from the Baden-Württem-
  90                        25.069                   7,24                Healthcare Industry - proven in the crisis                   berg Ministry of Economic Affairs, Labour and Housing,
Companies                   Employees         Billion euros taxable
                                                     turnover            During the coronavirus pandemic, the Healthcare In-          offers assistance to the state’s micro and small companies
                              BIOTECHNOLOGY                              dustry has shown how creative and agile it is. Within a      in implementing the MDR (chapter: Medical Technology
                                                                         short period of time, more than 190 vaccine projects have    Sector, page 18).
   184                          18.589                  4,19             been launched to date. CureVac AG, the start-up compa-
 Companies                      Employees        Billion euros taxable
                                                                         ny Prime Vector Technologies and BioCopy GmbH from           Focus on medical needs with future tech-
                                                                         Baden-Württemberg are among those involved in these          nologies and use of intelligent data
                                                                         projects . The medical technology sector reacted just as     Although the crisis and the increased regulatory require-
                                                                         creatively, converting production processes to the manu-     ments are a major test for the Healthcare Industry, they
                                                                         facture of personal protective equipment at an early stage   may also offer companies the opportunity to rethink
                                                                         and seeking new ways to develop respiratory equipment.       their business models, invest in smart processes, start
                                                                         Diagnostics manufacturers, including Spindiag GmbH,          collaborating with other companies and become much
                                                                         Trenzyme GmbH and Mediagnost GmbH, have been in-             more aware of new possibilities. Developments in the
                                                                         volved in developing test procedures for the detection       field of digitalisation and artificial intelligence, the uti-
                                                                         of viral RNA or SARS-CoV-2-specific antibodies. At the       lisation of real-world data as well as preventive and per-
                                                                         same time, the coronavirus pandemic has been driving         sonalised medicine are particular drivers of innovation.
                                                                         digitalisation in the healthcare sector and will, among      Cooperation and cross-sector networks will thus contin-
                                                                         other things, advance the field of eHealth. However, the     ue to become increasingly important in the future and
                                                                         pandemic has also plunged many healthcare companies          reduce sectoral thinking. With the patient as starting
                                                                         into crisis, as orders have fallen away or key raw mate-     point, developments in the healthcare sector will in fu-

         6   | Healthcare industry 2020                                                                                                                                Healthcare industry 2020 |     7
Healthcare Industry 2020 - Facts and Figures for Baden-Württemberg - MEDTECH PHARMA BIOTECH - Gesundheitsindustrie BW
Forum health region Baden-Württemberg
    ture be determined more by patients’ needs and less by        of 65.5 percent for Germany as a whole5. In general, the       Health at the forefront – science, business                   ics. To this end, the Baden-Württemberg government
    rigid structures. The data obtained in the real treatment     Healthcare Industry has proven itself to be an innovative      and healthcare thinking together.                             is providing 50 million euros in funding for implement-
    environment will therefore be key to providing valuable       and relatively independent driver of economic growth.                                                                        ing innovative projects from the Forum Health Region
    information for new products and processes.                                                                                  With the launch of the Forum Health Region                    Baden-Württemberg for 2020 and 2021. The spectrum of
                                                                  The innovation ecosystem in Baden-Würt-                        Baden-Württemberg in July 2018, the Baden-Württem-            Forum projects ranges from personalised medicine and
    An important economic factor for                              temberg                                                        berg government inaugurated a strategic process in which      new approaches in the field of patient care to combating
    Baden-Württemberg                                             The Healthcare Industry in Baden-Württemberg is                stakeholders from science, industry and patient care are      multidrug-resistant hospital germs. Key selection criteria
    In addition to the major challenges facing the healthcare     strongly represented with 1,104 companies that research,       given a platform for joint exchange and multidisciplinary     for the funded projects include ensuring that the benefit
    system, such as rising cost pressure and the shortage of      develop and/or manufacture in the state. In terms of           networking. Experts from the healthcare sector have en-       to patients is a central element, and that the projects are
    skilled workers, the increasing number of multimorbid,        the number of companies or employees, the state is the         tered into strategic dialogue with the ministries involved,   interdisciplinary and pursue new research and treatment
    chronically ill patients and the public’s heightened health      1
                                                                  no. Healthcare Industry location in Germany . 181  5/6/7
                                                                                                                                 working in three thematic blocks and tackling individu-       approaches.
    awareness has huge potential for increased sales and high     health-related start-ups were founded in Baden-Würt-           al topics in working groups. The aim is to break down
    employment. This is also reflected in the gross value add-    temberg between 2010 and 9/2020, most of them in the           sectoral thinking, develop the healthcare location to the     Elements of a joint strategy for Baden-Württemberg
    ed of the Healthcare Industry in Baden-Württemberg,           high-tech segment. Together with the state’s university        highest possible level and promote innovation that ben-       The development of an overall strategy is aimed at
    which amounted to around 17.8 billion euros in 2018. In       hospitals, research institutions and networks, a lively in-    efits patients.                                               strengthening Baden-Württemberg as an outstanding
    2018, more than one million people were employed in           novation ecosystem has been created here. One of the                                                                         healthcare location in the long term and defining the
    the healthcare sector in Baden-Württemberg .  1
                                                                  focal points of the CyberValley as a digitalisation hub, for   The Baden-Württemberg Ministry of Science, Research           necessary structural framework conditions at EU, feder-
                                                                  example, is the Healthcare Industry. The Forum Health          and the Arts is responsible for the “science and research”    al and state level. The spokesperson groups of the three
    Investment in research and development (R&D) is need-         Region Baden-Württemberg is a state supported effort to        thematic block, the Baden-Württemberg Ministry of Eco-        thematic blocks have done the initial groundwork and
    ed in order to generate innovation. Baden-Württemberg         further develop the Healthcare Industry and help it po-        nomic Affairs, Labour and Housing for the “business-re-       formulated strategy papers with recommendations for
    is well positioned in this area as shown by the figures       sition itself as a model location (chapter: The Healthcare     lated research, innovations, value creation and employ-       action for their respective thematic block. As an overall
    on R&D intensity collected in an EU-wide compari-             Industry at a Glance, page 9).                                 ment in the healthcare sector” thematic block, and the        strategy continues to be developed, findings and experi-
    son by the Baden-Württemberg Statistics Office. Here,                                                                        Baden-Württemberg Ministry of Social Affairs and Inte-        ence from the coronavirus pandemic will also be incor-
    Baden-Württemberg comes out top across all sectors as                                                                        gration is in charge of the “healthcare structures” themat-   porated in order to be structurally better prepared for
    the most innovative region in terms of invested nominal                                                                      ic block. For each thematic block there is a three-member     future pandemics. Regulations that safeguard the supply
    gross domestic product (GDP) in R&D (5.6 percent of                                                                          spokesperson group consisting of experts representing         of crisis-relevant drugs or medical products even in crisis
    nominal GDP) . As regards the number of patent appli-                                                                        the areas of science, economy and healthcare. The overall     situations are also being worked on as elements of an
    cations, Baden-Württemberg also takes first place with                                                                       coordination of the Forum Health Region Baden-Würt-           overall strategy. Equally necessary are efficient network-
    15,230 applications in 2019, followed by Bavaria and                                                                         temberg is the responsibility of the Baden-Württemberg        ing structures in the research field, aimed at gaining new
    North Rhine-Westphalia . Baden-Württemberg’s health-                                                                         State Ministry. BIOPRO Baden-Württemberg GmbH is in           insights for further strategic action through studies and
    care sector is the leading exporter with an export con-                                                                      charge of the administration for the Forum.                   research results.
    tribution of 38.2 billion euros, 94.7 percent of which is
    accounted for by the Healthcare Industry1. The high level                                                                    The healthcare sector is to be strengthened and further
    of demand from abroad is evidenced by the export ratio                                                                       developed through joint work on future-oriented top-

8   | Healthcare industry 2020                                                                                                                                                                                                 Healthcare industry 2020 |    9
Healthcare Industry 2020 - Facts and Figures for Baden-Württemberg - MEDTECH PHARMA BIOTECH - Gesundheitsindustrie BW

                                                                                                                         Stakeholders                                                 institutes and universities, health insurance companies,
                                                                                                                         The Forum Health Region Baden-Württemberg thrives            clusters and associations, companies in the Healthcare In-
                     1. Digitalisation                                                                                   on the active participation of stakeholders from all areas   dustry (biotechnology, pharmaceutical and medical tech-
              2. Strengthening translation                                                                               of Baden-Württemberg as a healthcare location who wish       nology companies) as well as from the health trade and
                                                                                                                         to help shape the strategic process. Around 480 actors are   health service sectors.
    3. Further development of academic education
                                                                                                                         already registered (as of June 2020). The broad spectrum
      with regard to a sustainable healthcare system
                                                                                                                         of participants includes experts from inpatient and outpa-   Anyone interested in participating can get in touch via
                                                                                                                         tient care, such as hospitals and nursing homes, research    the Forum’s website.
                                                     MINISTERIUM FÜR WIRTSCHAFT, ARBEIT UND WOHNUNGSBAU

                                                 MINISTY OF ECONOMIC AFFAIRS, LABOUR AND HOUSING

                                                              1. Digitalisation and artificial intelligence

                                                         2. Business-oriented research and innovations for
                                                                 targeted translation into application

                                                          3. Economic potential of personalised medicine

                                                 4. Potential of industry, services and trade in the healthcare sector

                                                    5. Company foundation, start-ups and new business models

                                                     6. Skilled labour and employment in the healthcare sector

                                                                        7. Regulatory framework
                                                                                                                                                                                         Information and contact
                                                                         8. Internationalisation
                                                                                                                                                                                         Forum Health Region Baden-Württemberg
                                                                                                                                                                                         office at BIOPRO Baden-Württemberg GmbH

1. Digitalisation and artificial intelligence (inter alia, electronic                                                                                                                    E-mail:
      patient records, patient protection, data usability, new                                                                                                                           Phone: +49 (0) 711 21 81 85 31
                         treatment options)                                                                                                                                         

    2. Personalised medicine (medical treatment and care)

          3. Pharmaceutical and medical device safety

            4. Care and technology in the care sector

                     5. Medical rehabilitation

                6. Prevention / health promotion

     10 | Healthcare industry 2020                                                                                                                                                                                   Healthcare industry 2020 | 11
Healthcare Industry 2020 - Facts and Figures for Baden-Württemberg - MEDTECH PHARMA BIOTECH - Gesundheitsindustrie BW
Medical Technology Sector

                                                                                                               Medical technology comprises a heterogeneous spectrum          turnover are the Tuttlingen area and the Rhine-Neckar
                     MEDICAL TECHNOLOGY
                                                                                                               of medical technology products with a medical purpose,         region, which is also the headquarter of Roche Diagnos-

  851                   52,092                    13.79                                                        intended for use on humans. These include dressing ma-         tics GmbH.
Companies               Employees          Billion euros turnover                                              terials and surgical instruments as well as implants, X-ray
                                                                                                               equipment and medical software. The certification of           A characteristic feature of medical technology in
                                                                                                               medical devices is currently subject to the German Medi-       Baden-Württemberg is the high number of micro and
                                                                                                               cal Devices Act, which will be mandatory replaced by the       small enterprises, which together make up more than 80
                                                                                                               MDR in May 2021.                                               percent of the region’s companies. This is where experts
                                                                                                                                                                              and traditionalists in the field of materials development
                                                                                                               In 2018, the 851 medical technology companies achieved         and refinement as well as production techniques come
                                                             Mannheim/                                         a taxable turnover of 13.79 billion euros with 52,092          together, along with developers and users of high-tech,
                                                      84     Heidelberg
                                                                                                               employees subject to social security contributions. This       novel biomaterials and artificial intelligence. This diversi-
                                                                                 Heilbronn/Franken             makes Baden-Württemberg the no. 1 location for medical         ty of companies and entrepreneurship and the close links
                                                                                                               technology in Germany.                                         with centres of excellence, universities and university
                                                                                                                                                                              hospitals in Baden-Württemberg enable new develop-
                                                                                                               Shaping the future with tradition, diversity                   ments to emerge across value chains and sectors.
                                     Karlsruhe                                                                 and know-how
                                                                                                               Within the Healthcare Industry, medical technology             Pooling know-how, using networks and
                                                                        103                 Aalen/Heidenheim   companies represent by far the largest group in terms of       promoting the entrepreneurial spirit
                                     61                                                                        number of companies, turnover and number of employ-            In the period between 2010 and 9/2020, 98 medical tech-
                                                                                                     15        ees. The strong small- and medium-sized companies in           nology companies were founded in Baden-Württemberg,
                                                 44                                                            the medical technology industry are concentrated around        18 of which were established between 1/2018 and 9/2020.
                                       Freudenstadt                                                            Tuttlingen/Villingen-Schwenningen, in the Freiburg/Of-         The regions with a high number of start-ups over the last
                                                                                                               fenburg/Lörrach area and around Stuttgart and Reutlin-         ten years are Mannheim/Heidelberg with 21 start-ups
                                                                                                               gen/Tübingen. Among the regions with the highest               and Schwarzwald-Baar-Heuberg with 20 start-ups. These
                                            286                                                                          50 %                                                    32 %                                 14 %            4%
                       Lörrach                                                                                           Medical technology companies in Baden-Württemberg in 2018 by employment size class

                                                                 Konstanz/Oberschwaben                                   2% 9%        18 %                 71 %

                                                                              46                                         Turnover of medical technology companies in Baden-Württemberg in 2018 by employment size class

                                                                                                                              < 10       10 - 49       50 - 249       ≥ 250

     12 | Healthcare industry 2020                                                                                                                                                                             Healthcare industry 2020 | 13
Healthcare Industry 2020 - Facts and Figures for Baden-Württemberg - MEDTECH PHARMA BIOTECH - Gesundheitsindustrie BW
Medical technology companies founded in Baden-Württemberg between 1/2018 and 9/2020

                                                                                                                                                                                                        Company                                  Location                          Field of activity

                                                                                                                                                                                                        Derma Intelligence GmbH                  Mannheim                          eHealth
                                                                                                                                                                                                        evid UG                                  Mannheim                          eHealth
                                                                                                                                                                                                                                                                                   Dental products, therapeutic systems and
                                                                                                                                                                                                        Freiburger Medizintechnik GmbH           Freiburg
                                                                                                                                                                                                                                                                                   Contract production, dental products,
                                                                                                                                                                                                        I.C. Lercher Solutions GmbH              Stockach
   start-ups are involved across all fields of activity, with the                           Fields of activity of medical technology companies in
                                                                                                                                                                                                        imm Innovative Medical
                                                                                            Baden-Württemberg (companies may have several                                                                                                        Mannheim                          Surgical instruments

   eHealth sector showing considerable growth in recent                                     fields of activity)                                                                                         Mannheim GmbH

   years. Half of all start-ups between 1/2018 and 9/2020 are                                                                                                                                           implacit GmbH                            Mannheim                          eHealth, software
                                                                                                               Surgical instruments
                                                                                                                                                                                                        Kamedi GmbH                              Eggenstein-Leopoldshafen          eHealth, therapeutic systems and devices
   active in this segment.                                                                         Therapeutic systems and devices
                                                                                                                                                                                                        LUNA cybernetics GmbH                    Weingarten                        Exoprostheses
                                                                                                        Implants and exoprostheses
                                                                                                                                                                                                        MR Shim GmbH                             Reutlingen                        Diagnostics
   The spirit of innovation and entrepreneurship in                                                                                                                                                     ReHub GmbH                               Reutlingen                        eHealth, therapeutic systems and devices
                                                                                                                    Dental products
   Baden-Württemberg must continue to be strengthened                                                                                                                                                                                                                              Hygiene, protection and sterilisation
                                                                                                                      Consumables                                                                       WiMedical UG                             Singen
   and driven forward through intensive networking and co-                                                                                                                                                                                                                         equipment
                                                                                            Healthcare-IT, eHealth and telemedicine
   operation in order to counter the pressure from global or                                                                                                                                            3a-diagnostics GmbH                      Frickenhausen                     Diagnostics
                                                                                               Patient and point-of-care diagnostics
                                                                                                             Hygiene, sterilisataion,                                                                   AIRAmed GmbH                             Tübingen                          eHealth, software
   non-industry competitors.                                                                                   protection equipment                                                                     Becure GmbH                              Mannheim                          eHealth, therapeutic systems and devices

                                                                                            Doctor’s practice and hospital equipment
                                                                                                                                                                                                        Hellstern medical GmbH                   Wannweil                          Doctor’s practice and hospital equipment
   The Medical Device Regulation and other                                                                       In vitro diagnostics
                                                                                                                                                                                                        Living Brain GmbH                        Heidelberg                        eHealth, software
                                                                                                                  Imaging methods
   challenges                                                                                                                                                                                           Thericon GmbH                            Mannheim                          Imaging methods, endoscopy
                                                                                                          Optical and laser systems
   The MDR corrigendum of December 2019 extended

                                                                                                        Anaesthesia and respiration                                                                     Midaia GmbH                              Heidelberg                        eHealth
   the transition period for manufacturers of class Ir (class                                                                                                                            Gründungen
                                                                                                                                        0 5 10 15 20 25 30 35 40
   I, reusable) products. On 23rd April 2020, the Europe-
                                                                                                                                        Percentage of companies
   an Commission’s proposal to delay the application date                                                                               active in the respective
                                                                                                                                        field of activity
   by one year from 26th May 2020 to 26th May 2021 for
   manufacturers of in vitro medical devices was approved                                   The EU regulation on In Vitro Diagnostic Medical Devic-                                      Medical technology companies founded in                                    Medical technology moving towards the
                                                                                                                                                                                         Baden-Württemberg between 2010 und 2019
   by the European Parliament and Council. The decision                                     es (IVDR) will be mandatory from 26th May 2022 after                                                                                                                    digital era
   was partly due to concerns over the coronavirus pandem-                                  a five-year transition period. Here too, manufacturers of                                                                                                               The digitalisation of healthcare is changing the require-
   ic. Although this gives the industry a breathing space, it                               in vitro diagnostic devices (IVD) will face major hurdles                                                                                                               ments for modern medical technology. The Digital Care

                                                                                                                                                                   number of companies
   must continue to make every effort to meet the increased                                 when implementing the regulation and are advised to ap-                                                                                                                 Act and the Digital Health Applications Ordinance are
   regulatory requirements for medical devices.                                             ply and implement it at an early stage.                                                       6
                                                                                                                                                                                                                                                                    aimed at making the industry more dynamic and legisla-
                                                                                                                                                                                          4                                                                         tors want digital health applications to enter the medical
   Medical Technology Index for Baden-Württemberg: turnover                                 In addition, the coronavirus pandemic is putting pressure                                     2                                                                         device market much faster. The first two “health apps on
   development from 2007 to 2018 in million euros
                                                                                            on supply chains, orders are dropping below average and                                       0                                                                         prescription” were added to the list of digital health ap-









                                                                                            many manufacturers have had to announce short-time                                                                                                                      plications by the Federal Institute for Drugs and Medical
                                                                                            working. According to BVMed’s Autumn 2020 Survey,                                                                                                                       Devices (BfArM) in October 20209. After the Kranken-
                                                                                            companies are expecting a 4.9 percent drop in sales (com-                                    basic documents, information events and individual ex-                     hauszukunftsgesetz (Hospital Future Act) passed in the
   40                                                                                       pared to the previous year: sales up 3.3 percent) .      8
                                                                                                                                                                                         pert consultation days (see page 18). The MDR & IVDR                       Bundestag in September 2020, the German federal gov-
   30                                                                                                                                                                                    Fast-track Support BW, which has so far focused on MDR,                    ernment is also making investment funds of 3 billion eu-
   20                                                                                       The MDR & IVDR Fast-track Support BW programme                                               will be extended to IVD producers and will be available                    ros available for the digitalisation of hospitals10.
   10                                                                                       offers the medical technology companies in Baden-Würt-                                       in an adapted format from 2021. More information will
                                                                                            temberg practical support for implementing the MDR                                           shortly be available on the












                                                                                            and IVDR, including, for example, help with preparing                                        website.

14 | Healthcare industry 2020                                                                                                                                                                                                                                                                          Healthcare industry 2020 | 15
Selected investments, acquisitions as well as collaborations and licensing agreements made by
   Baden-Württemberg medical technology companies in the period from 1/2018 to 9/2020


              Company                       Location                   Field of activity                           Investment volume                        Type of financing               Investors

              monikit UG                    Stuttgart                  Epilepsy diagnostics                        EUR 1.86 million                         Project financing               Life Science Inkubator GmbH

              SpinDiag GmbH                 Freiburg im Breisgau       Point-of-care screening system              EUR 3 million                            2. financing round, Series A    Business Angels from Baden-Württemberg

                                                                                                                                                                                            Santo Venture Capital, LBBW Venture
              CorTec GmbH                   Freiburg im Breisgau       Neuroprothetics                             EUR 13 million                           Financing round

              Curetis N.V.                  Holzgerlingen              Molecular diagnostics products              EUR 6.5 million                          Financing                       EIB, Yorkville
                                                                                                                                                            Expansion of Series A funding   WBG Pflegeheime and a new investor as
              SpinDiag GmbH                 Freiburg im Breisgau       Point-of-care screening system              EUR 4 million
                                                                                                                                                            round                           well as existing investors

              Curetis                       Holzgerlingen              Molelcular diagnostics products             EUR 20 million                           Convertible loan                Issuance of Curetics N.V. convertible notes
              SpinDiag GmbH                 Freiburg im Breisgau       Point-of-care screening system              EUR 6 million                            Project funding                 Baden-Württemberg government
                                                                                                                                                                                            Existing investors as well as Think.Health
              SpinDiag GmbH                 Freiburg im Breisgau       Point-of-care screening system              EUR 16.3 million                         Series B financing round

                                                                                                                                                                                            WEFA Inotec GmbH, High-Tech
                                                                                                                                                                                            Gründerfonds, Mittelständische
                                                                       Technology for the functionalisation of
              stimOS GmbH                   Konstanz                                                               -                                        Series A financing              Beteiligungsgesellschaft Baden-
                                                                       implant materials
                                                                                                                                                                                            Württemberg, founding shareholder


              Company                       Location                   Field of activity                           Buyer

              EIT Emerging Implant
                                            Tuttlingen                 Spinal cord implants                        Johnson & Johnson Medical GmbH, Norderstedt
              Technologies GmbH

              GEHRING CUT AG                Matzingen, Schweiz         Surgical instruments                        KLINGEL medical metal GmbH, Pforzheim
              Hain Lifescience GmbH         Nehren                     Molecular diagnostics                       Bruker Corporation, Billerica, MA, USA

              Bächler Feintech AG           Hölstein, Schweiz          Surgical instruments                        KLINGEL medical metal GmbH, Pforzheim

              FREI AG                       Kirchzarten                Medical training devices and therapy beds   Zimmer MedizinSysteme GmbH, Neu-Ulm

              Curetis                       Weil im Schönbuch          Diagnostics                                 Fusion: OpGen, Gaithersburg, Maryland, USA

              Stuckenbrock Medizintechnik
                                            Tuttlingen                 Surgical instruments                        KLS Martin Group, Tuttlingen

    Cooperations and licensing agreements

              Company                       Location                   Partner company                             Category

                                                                       Beijing Clear Biotech Co., Ltd., Beijing,

              Curetis N.V.                  Holzgerlingen                                                          Strategic cooperation

16 | Healthcare industry 2020                                                                                                                                                                                Healthcare industry 2020 | 17
MDR Fast-Track Support BW
   The MDR came into force in May 2017 and will become           In summer 2019, the Baden-Württemberg Ministry of Eco-    aimed at saving time and resources for the companies af-       holders was initiated so that first meetings can be started
   fully effective on 26th May 2021. In addition to a harmo-     nomic Affairs, Labour and Housing made funds available    fected. This includes jointly preparing basic documents        in due time.
   nised legal framework for the marketing of medical devic-     for a MDR Fast-Track Support BW programme to help         for certification, developing guidelines on specific issues
   es, the European Union’s main objective is to ensure the      the medical technology sector in Baden-Württemberg        and sharing newly acquired information at events. In ad-       In addition to topic-specific information events, compa-
   safety of these products for users. This results in new re-   implement the MDR. The aim of this MDR Fast-Track         dition, access to clinical trial centres will be facilitated   nies can raise specific questions with experts at regular
   quirements for the industry, which pose major challenges      Support BW is to offer practical, user-oriented support   to help companies that are required to conduct clinical        online consultation days.
   for micro and small companies in particular, but also for     services for implementing the MDR by the end of 2021.     trials due to MDR. BIOPRO Baden-Württemberg GmbH
   some medium-sized companies.                                  The programme consists of five measures (see box below)   is coordinating the MDR Fast-Track Support BW.                 The information and orientation aids obtained and com-
                                                                                                                                                                                          piled as part of MDR Fast-Track Support BW as well as
                                                                                                                           Interim status and outlook                                     useful contributions by third parties are pooled and made
                                                                                                                           Eighteen basic documents were completed last year.             available via the MDR & IVDR Guide BW (https://mdr-
                                                                                                                           Nine further product groups are currently being worked
                                                                                                                           on, and consortia are in the process of being formed for
   Product Group-Specific Shared Documents                                                                                 twelve product groups. The completed basic documents
   Company consortia are developing basic documents for individual medical device groups, which can be used as             can also be purchased by companies outside Baden-Würt-
   a basis for creating individual certification documents.                                                                temberg and have already been shared over 300 times
                                                                                                                           within and outside the consortia.
   MDR Expert Talks BW
   In the expert rounds, quality management and regulatory affairs specialists and service providers discuss               A first expert panel on clinical evaluation identified a
   MDR-relevant issues and develop guidelines on the various topics.                                                       considerable need for information. To this end, a series of
                                                                                                                           virtual events, “A focus on clinical trials”, provided prac-
   Clinical Study Guide BW                                                                                                 tical information on how to carry out successful clinical
   The creation of a central information hub with a guide function will facilitate access to clinical trial centres and    evaluations for existing products and innovations. Fur-
   provide information on the subject.                                                                                     ther expert panels are currently being set up.

   MDR Roundtables                                                                                                         In order to facilitate access to clinical study centers and
   The Roundtables provide the opportunity for an informal exchange between relevant stakeholders such as noti-            to provide support for the many questions regarding
   fied bodies, supervisory authorities, business associations and service providers in order to minimise uncertainty      clinical trials, various aspects of this topic are discussed       All information on MDR Fast-Track Support BW is
   in the interpretation of the new regulation.                                                                            with experts, manufacturers and study center contacts.             available at
                                                                                                                           Afterwards, information is made available in the form of      
   MDR Fast-Track Support Events                                                                                           a Clinical Study Guide BW.
   These are events where the results and findings of the MDR Fast-track support BW programme as well as rele-                                                                                Please feel free to send us your suggestions or
   vant topics relating to MDR will be presented in the form of information sessions.                                      MDR-relevant topics were identified for the MDR                    questions for Expert Talks or Roundtables.
                                                                                                                           Roundtables and the exchange with the different stake-             E-mail:

18 | Healthcare industry 2020                                                                                                                                                                                             Healthcare industry 2020 | 19
Pharmaceutical Industry and
                                                                                                                          Pharmaceutical industry
                                                                                                                          Fighting the coronavirus pandemic with                          Location-loyal medium-sized and large com-
                                                                                                                          creativity and know-how                                         panies

  90                       25.069                               7,24                                                      The coronavirus pandemic and the development of ap-             The pharmaceutical industry in Baden-Württemberg is
Companies                  Employees                 Billion euros turnover                                               propriate vaccines and therapies against SARS-CoV-2 are         loyal to its location. The number of companies based in
                                                                                                                          the defining issues of 2020. The development of new             the state has remained stable for many years and current-
                             BIOTECHNOLOGIE                                                                               drugs and vaccines usually takes 10 to 20 years. However,       ly comprises 90 companies that research, develop and/
                                                                                                                          the Robert Koch Institute indicates that the first vaccines     or manufacture here. In 2018, they achieved a taxable
   184                          18.589                           4,19                                                     against SARS-CoV-2 can be expected to be approved               turnover of 7.24 billion euros with 25,069 employees sub-
 Companies                      Employees               Billion euros turnover
                                                                                                                          in sufficient quantities as early as 2021 . The fully se-       ject to social security contributions. The sector reinvests
                                                                                                                          quenced genome of the novel coronavirus has been avail-         more than 14 percent of its turnover in research and de-
                                                                   Mannheim/                                              able since mid-January 2020. Since then, collaborations         velopment projects, making it the sector with the high-
                                                                                                                          have developed across national borders, resulting in over       est proportion of internal expenditure on research and
                                                            8      63                                                                                          12
                                                                                                                          190 vaccine development projects . Pharmaceutical and           development in relation to turnover13. Five pharmaceuti-
                                                                                                                          medical biotechnology companies are responsible for the         cal companies were founded in Baden-Württemberg be-
                                                                                       1           2                      development of these therapies and vaccines.                    tween 2010 and 9/2020. These include ZentriForce Phar-
                                                                                                                                                                                          ma Research GmbH in Heidelberg, which offers contract
                                                                                                                          In Baden-Württemberg, a large number of pharmaceu-              research and analysis for the pharmaceutical industry
                                                                                                                          tical and biotechnology companies and research insti-           (founded 04/2019).
                                            16                              13        12               Aalen/Heidenheim   tutes are working on new therapies and vaccines against
                                                            2                                                             SARS-CoV-2, including CureVac AG, Atriva Therapeu-              Today, due to the major hurdles involved in drug reg-
                                          16                         Stuttgart

                                                        4                                                      3          tics GmbH and the start-up Prime Vector Technologies            istration as well as the high capital expenditure, phar-
                                                                                                                          GmbH. Companies in Baden-Württemberg, such as Pfiz-             maceutical companies that combine production, regis-
                                               Freudenstadt                                                               er Manufacturing Deutschland GmbH in Freiburg and               tration, marketing, research and development are rarely
                                                                                                                          TEVA GmbH in Ulm, are also involved in securing the             established. The biotechnology sector is proving to be an
                                                                        5        29
                                                                                                                          supply of crisis-relevant drugs.                                innovative partner and provider of ideas here, contribut-
                                                                                                                                    22 %                       32 %                                22 %                      23 %
                                                    Villingen-                                         12
                           Lörrach                                                                                                  Companies in the pharmaceutical industry in Baden-Württemberg in 2018 by employment size classes

                                                                        Konstanz/Oberschwaben                                        3 % 4 % 18 %                   75 %
                                                                                      10       9
                                39                                                                                                  Turnover of the pharmaceutical industry in Baden-Württemberg in 2018 by employment size classes

                                                                                                                                           < 10      10 - 49          50 - 249    ≥ 250

         20 | Healthcare industry 2020                                                                                                                                                                                     Healthcare industry 2020 | 21

                                                                                                                                  Medical biotechnology
       Fields of activity of the pharmaceutical industry in         lead to far fewer side effects. Pfizer’s Healthcare Hub was   On course for growth with biotechnology                         coronavirus pandemic. Company founders are struggling
       Baden-Württemberg (campanies may have several
       fields of activty)                                           founded in Freiburg in March 2018. In its search for digi-    The attractiveness of the state is also shown by the fact       with liquidity bottlenecks and the absence of financing
        Phytopharmaceuticals                                        tal patient solutions, Pfizer’s Healthcare Hub seeks prox-    that, in addition to pharmaceutical companies, a large          rounds. The Baden-Württemberg Ministry of Economic
                 Homeopathy                                         imity to life sciences start-ups and spin-offs and focuses    number of medical biotechnology companies enrich the            Affairs, Labour and Housing has reacted to this situation
     Classical pharmaceuticals                                      on flexible interaction models. Using simulation software     overall offer in Baden-Württemberg. While the pharma-           and is now promoting early-stage financing by expand-
Contract research/development                                       from the Karlsruhe-based start-up GoSilico GmbH, for          ceutical industry provides implementation and produc-           ing the Start-up BW Pre-Seed programme and through
          Contract production
                                                                    example, drugs can be brought to market faster and more       tion process know-how, among other things, the mostly           the newly established Start-up BW Pro-Tect support pro-
                Generic drugs
                                                                    cost-effectively because downstream (purification) pro-       smaller, agile biotech companies or start-ups drive inno-       gramme (chapter: Company Foundation and Financing,
                                 0         10           20     30   cesses can be digitally simulated and scaled.                 vation in the sector.                                           page 34)14.
                                 Percentage of companies by
                                 field of activity
                                                                    To survive against global competition, agile cooperation      Baden-Württemberg is home to 184 medical/red biotech-           The Mannheim/Heidelberg (29 start-ups since 2010),
       ing to a diversification of risk through complex financing   and networks are valuable instruments for staying one         nology companies that research, develop and/or manufac-         Karlsruhe (15 start-ups since 2010) and Reutlingen/
       models, cooperation and licensing agreements.                step ahead of the competition. Baden-Württemberg offers       ture here. In 2018, they generated a taxable turnover of        Tübingen (13 start-ups since 2010) regions are particularly
                                                                    a large number of cooperation partners from industry and      4.19 billion euros with 18,589 employees subject to social      strong as far as the foundation of new companies is con-
       In addition to a large number of owner-managed com-          science. Research and technology parks and incubators         security contributions.                                         cerned. The Rhine-Neckar region plans the first Europe-
       panies and micro and small enterprises, Baden-Württem-       also offer interesting concepts and space to set up offices                                                                   an BioLabs life sciences start-up incubator in Heidelberg,
       berg is also home to a number of subsidiaries of mul-        and research laboratories and to establish low-threshold      Coronavirus start-up support and expansion                      a sign that it is planning to expand and secure this leading
       tinational corporations. The companies’ portfolios range     contact between big pharma and start-ups.                     of start-up centres                                             position in the future15.
       from generics to phytopharmaceuticals and homeopathic                                                                      Over 78 medical biotechnology companies have been
       drugs, which enrich the traditional drug manufacturing                                                                     founded in Baden-Württemberg since 2010. This rep-              A leader in biopharmaceutical production
       market with valuable therapy options.                                                                                      resents 40 percent of all biotechnology companies in            Germany is no. 1 in Europe and no. 2 behind the USA
                                                                                                                                  Baden-Württemberg. 17 companies were founded in the             regarding the manufacture of biopharmaceuticals16. The
       Using the potential of new technologies                                                                                    period between 1/2018 and 9/2020. The fact that the num-        region in the area around Laupheim, Ulm and Biber-
       and initiating agile cooperation                                                                                           ber of start-ups in the first half of 2020 is relatively low    ach is particularly well known for developing and man-
       The development of new drugs is costly, lengthy and                                                                        compared to previous years can be largely ascribed to the       ufacturing biopharmaceuticals in Baden-Württemberg.
       high-risk. At the same time, the pharmaceutical market
       is highly regulated and global value chains are complex.
                                                                                                                                            53 %                                                         24 %                       20 %                 4%
       Although the challenges facing the pharmaceutical indus-
       try will continue to increase under the influence of glob-
       al developments, the possibilities are almost unlimited.                                                                             Biotechnology companies in Baden-Württemberg in 2018 by employment size class

       Digitalisation continues to gain momentum, and access
                                                                                                                                            1 %4 % 9 %        86 %
       to data from the real world, therefore the user world, can
       drive development ever more precisely towards tailored
       forms of therapy for sub-populations of patients that                                                                                Turnover of biotechnology companies in Baden-Württemberg in 2018 by employment size class

                                                                                                                                                 < 10        10 - 49       50 - 249       ≥ 250

   22 | Healthcare industry 2020                                                                                                                                                                                                  Healthcare industry 2020 | 23

                                                                                                                                                                       Biotechnology companies founded in Baden-Württemberg between 1/2018 bis 9/2020

                      About half the turnover of biotechnology companies in                           Fields of activity of biotechnology companies in
                                                                                                      Baden-Württemberg (companies may have several                              Company                                  Location                   Field of activity
                      Baden-Württemberg is generated here. Boehringer In-                             fields of activity)
                      gelheim is currently investing 230 million euros in the                                                 analytics
                                                                                                                                                                                 Aquarray GmbH                            Eggenstein-Leopoldshafen   Analytics

                      construction of a new development centre in Biberach to                                  consumables and devices                                           AVA Therapeutics GmbH                    Denzlingen                 Therapeutics
                      meet the growing demand for biopharmaceuticals. This                                                 therapeutics
                                                                                                                                                                                 candidum GmbH                            Stuttgart                  Bioinformatics, service
                      Biologicals Development Centre is scheduled for com-                              contract research/-development
                                                                                                                     custom production

                      pletion at the end of 2020. Rentschler Biopharma SE and                                                                                                    CeCaVa GmbH & Co. KG                     Tübingen                   Therapeutics
                      Vetter Pharma-Fertigung GmbH & Co. KG announced a
                                                                                                                                                                                 Navitect Bio GmbH                        Heidelberg                 Diagnostics, service
                      strategic cooperation in a press release in July 2020 aimed                                                         0    10    20     30    40
                                                                                                                                          Percentage of companies by
                      at making new therapies available to patients even faster                                                                                                  pantaBio AG                              Stuttgart                  Software
                                                                                                                                          field of activity
                      in future (chapter: Pharmaceutical Industry, page 30/31).                                                                                                  PixelBiotech GmbH                        Schriesheim                Analytics, service
                      Rentschler Biopharma SE is also involved in producing a                         The development of new therapies is risky and very cost-
                      potential coronavirus vaccine .         17
                                                                                                      ly. Many previously promising developments fail in later                   AaviGen GmbH                             Heidelberg                 Therapeutics

                                                                                                      phases of development and consume a great deal of re-                                                                                          Contract research and development,
                                                                                                                                                                                 ARAXA Biosciences GmbH                   Heidelberg
                      The industry’s expertise must continue to focus on new                          sources. Translational medicine, i.e. the early translation                                                                                    therapeutics

                      technologies and developing new and innovative forms                            of research results into clinical practice, will help to pre-              AUCTEQ Biosystems GmbH                   Mannheim                   Consumables and devices
                      of therapy, while production processes must be mapped                           vent this from happening. Medical biotechnology, which
                                                                                                                                                                                 Intavis Peptide Services GmbH & Co. KG   Tübingen                   Contract production, service

                      safely, smartly and effectively. In the field of gene and                       is dependent on external funding, stands to benefit from
                      cell therapies, Sartorius Stedim Cellca GmbH has already                        the intensive exchange between clinics and research and                    Klar2O GmbH                              Bruchsal                   Analytics, therapeutics

                      commissioned and invested 30 million euros in a new of-                         the early translation of research results into therapy op-
                                                                                                                                                                        GmbH                              Eggenstein-Leopoldshafen   Analytics, devices
                      fice and laboratory building with over 100 employees in                         tions.
                      the Ulm Science Park. CellGenix GmbH announced the                                                                                                         Opto Biolabs UG                          Freiburg im Breisgau       Consumables and devices

                      expansion of its production facilities in October 2020 in                       The Tübingen-based biotech companies CureVac AG                            Prime Vector Technologies GmbH           Tübingen                   Therapeutics
                      response to steadily increasing demand for materials for                        and Immatics Biotechnologies GmbH were founded in
                                                                                                                                                                                 Axxelera UG                              Karlsruhe                  Bioinformatics
                      gene and cell therapies.                                                        2000 as spin-offs from the Department of Immunology

                                                                                                      at the University of Tübingen under the leadership of                      Fast Forward Discoveries GmbH            Mannheim                   Consumables and devices
                      Foundation of biotechnology companies in                                        Prof. H.-G. Rammensee. Translational immunology is at
                      Baden-Württemberg between 2010 and 2019
                                                                                                      the centre of his research. Both companies made a re-
                                                                                                      markable start on the Nasdaq technology stock exchange
                                                                                                      - Immatics in July 2020 and CureVac in August 2020.
number of companies











24 | Healthcare industry 2020                                                                                                                                                                                                                                    Healthcare industry 2020 | 25
Selected investments, acquisitions, cooperation and licensing agreements as well as stock market
   launches of biotechnology companies in Baden-Württemberg between 1/2018 and 9/2020


              Company                     Location                     Field of activity                            Type of financing                        Investment volume              Investors

                                                                                                                                                                                            Meneldor, High-Tech Gründerfonds and
              Atriva Therapeutics GmbH    Tübingen                     Antiviral therapy                            Series A financing                       EUR 1.25 million
                                                                                                                                                                                            company founders
                                                                                                                                                                                            High-Tech Gründerfonds and two private
              Cytena GmbH                 Freiburg im Breisgau         Cell separation systems                      Series A financing                       EUR 3 million

              Heidelberg Pharma AG        Ladenburg                    Cancer therapy                               Milestone payment                                                       Link Health Co.
                                                                       Individual simulation solutions for
              HQS Quantum Simulations                                                                                                                                                       High-Tech Gründerfonds, Unternehmertum
                                          Karlsruhe                    conventional computers and quantum           Seed financing                           EU 2.3 million
              GmbH                                                                                                                                                                          Venture Capital Partners und btov Partners

                                                                       Development and production of ­                                                                                      Federal Republic of Germany by way of
              CureVac AG                  Tübingen                                                                  Growth financing                         EUR 300 million
                                                                       mRNA-based vaccines                                                                                                  KfW
                                                                       Development and production of                                                                                        European Investment Bank and European
              CureVac AG                  Tübingen                                                                  Loan                                     EUR 75 million
                                                                       mRNA-based vaccines                                                                                                  Commission

                                                                       Development and production of                                                                                        Qatar Investment Authority (QIA) and other
              CureVac AG                  Tübingen                                                                  Private financing round                  USD 126 million
                                                                       mRNA-based vaccines                                                                                                  investors
                                                                                                                                                                                            Boehringer Ingelheim Venture Fund
              HepaRegeniX GmbH            Tübingen                     Liver disease therapy                        Series B financing                       EUR 11 million                 GmbH, Novo Holdings A/S, High-Tech
                                                                                                                                                                                            Gründerfonds, Coparion and Ascenion


              Company                     Location                     Field of activity                            Buyer                                                                   Value

              Dispendix GmbH              Stuttgart                    Liquid handling systems                      CELLINK AB, Gothenborg, Sweden                                          EUR 5 million

              cytena GmbH                 Freiburg im Breisgau         Cell separation systems                      BioCopy GmbH, Freiburg im Breisgau                                      EUR 30.25 million

              Biametrics GmbH             Tübingen                     Label-free biosensor technology              BioCopy GmbH, Freiburg im Breisgau                                      -

              Immatics Biotechnologies                                                                              Fusion: Arya Sciences Acquisition Corp. (Houston) with Immatics
                                          Tübingen                     Cancer immunotherapies                                                                                               -
              GmbH                                                                                                  Biotechnologies and name change to Immatics N.V.

    Cooperations and licensing agreements

              Company                     Location                     Partner company                              Category                                                                Financing amount

                                                                       Genentech Inc., San Francisco, California,   Affimed will use its ROCK platform in order to discover interesting
              Affimed GmbH                Heidelberg                                                                                                                                        In total USD 5 billion
                                                                       USA                                          immunotherapics for Genentech/Roche

              Expedeon AG                                              Quanterix Corporation, Lexington,
                                          Heidelberg                                                                Supply and licensing agreement for proprietary immunoassay technology
              (früher: SYGNIS AG)                                      Massachussets, USA

              Heidelberg Pharma
                                          Heidelberg                   Magenta Therapeutics, Cambridge, USA         Resarch agreement for the development of antibody drug candidates       USD max. 334 million
              Research GmbH

              Immatics Biotechnologies                                                                              Research and licensing partnership for the development of new next-
                                          Tübingen                     Genmab A/S, Copenhagen, Denmark                                                                                      USD max. 3 billion
              GmbH                                                                                                  generation cancer immunotherapies

26 | Healthcare industry 2020                                                                                                                                                                                 Healthcare industry 2020 | 27
Cooperation and licensing agreements

              Company                      Location                      Partner company                             Category                                                                      Financing amount

              Immatics Biotechnologies                                   Celgene Corporation, Summit, New Jersey,
                                           Tübingen                                                                  Strategic cooperation                                                         Approximately EUR 1.45 billion
              GmbH                                                       USA

              Heidelberg Pharma Research
                                           Heidelberg                    Magenta Therapeutics, Cambridge, USA        Development and marketing rights                                              USD 34 million

              Heidelberg Pharma Research
                                           Ladenburg                     Emergence Therapeutics AG, Duisburg         Licensing and development agreement                                           -

                                                                         Schepens Eye Research Institute of

              CureVac AG                   Tübingen                      Massachusetts of the Harvard Medical        Exclusive research cooperation                                                -
                                                                         School, Boston, USA

                                                                         Coalition for Epidemic Preparedness
              CureVac AG                   Tübingen                                                                  Partnership agreement                                                         USD 34 million

                                                                         Yale University, New Haven, Connecticut,
              CureVac AG                   Tübingen                                                                  Research cooperation                                                          -

              CureVac AG                   Tübingen                      Genmab A/S, Copenhagen, Denmark             Strategic development partnership                                             -

                                                                         Coalition for Epidemic Preparedness         CEPI provides CureVac with funds for the development of a vaccine
              CureVac AG                   Tübingen                                                                                                                                                Up to USD 8.3 million
                                                                         Innovations (CEPI), Oslo                    against coronavirus nCoV-2019

                                                                                                                                                                                                   GSK makes equity investment of EUR 150
                                                                         GlaxoSmithKline (GSK), Brentford,
              CureVac AG                   Tübingen                                                                  Strategic cooperation agreement                                               million in CureVac and one-off payment of
                                                                         Middlesex, UK
                                                                                                                                                                                                   EUR 120 million

              Immatics Biotechnologies                                                                               Strategic collaboration to develop T-cell therapeutics for the treatment of   EUR 45 million (possibly further milestone
                                           Tübingen                      GlaxoSmithKline, Brentford, Middlesex, UK
              GmbH                                                                                                   solid tumours                                                                 payments)

              Rentschler Biopharma SE      Laupheim (und Milford, USA)   Genmab A/S, Copenhagen, Denmark             Strategic cooperation                                                         -

              Velabs Therapeutics GmbH     Heidelberg                    Alytas Therapeutics, Jena                   Licensing agreement                                                           -

    Stock market launch


              CureVac AG

              Immatics N.V.

28 | Healthcare industry 2020                                                                                                                                                                                       Healthcare industry 2020 | 29
Dr. Frank Mathias,
                                                                                                                                                 CEO Rentschler Biopharma SE
   Strategic Collaboration between                                                                                                     Peter Sölkner, Managing Director Vetter
   Rentschler Biopharma and Vetter                                                                                                         Pharma-Fertigung GmbH & Co. KG

   Doing it the Swabian way:                                     drug production. The resulting trust is extremely valuable       mized workflows for a more efficient “time-to-market”.          Under “normal” circumstances it is easy to overlook the
   joining forces to bring novel therapies to                    when it comes to their alliance, and the close proximity of      Rentschler Biopharma and Vetter are proud to break new          larger context of one’s actions. The pandemic has made
   patients faster                                               our company headquarters, in Baden-Wuerttemberg, is a            ground in Baden-Wuerttemberg with this alliance and are         our industry all the more significant and shown what it
                                                                 major contributing factor. Our corporate cultures are simi-      seeking to help turn the region into a global healthcare        can contribute to people’s well-being. Fast and safe access
   The COVID-19 pandemic has caused setbacks for most            lar, we have similar roots and we speak the same language.       hub and create attractive opportunities for companies,          to essential vaccines and medicines is a goal that can be
   global industries. With one major exception: the phar-                                                                         employees and entrepreneurs.                                    achieved through cooperation and alliances.
   maceutical industry. The industry has rarely been more        Equally important is the fact that Baden-Wuerttemberg
   active in the development of vaccines and therapeutic         is increasingly establishing itself as a central, internation-   Optimised product path
   drugs. New collaborations, fundraising and IPOs, clinical     al hub for biopharmaceutical development and produc-             The biopharmaceutical market is developing rapidly with
   trials and regulatory approvals have happened at an un-       tion through other world-class companies. In addition,           the emergence of new, highly innovative therapies for a
   precedented pace - all with the aim of ensuring the fastest   renowned universities such as Heidelberg, Tubingen and           wide range of indications. To meet the dynamic demands
   possible public access to vaccines and medication.            Ulm, as well as a whole range of small- and medium-sized         of the market, we rely on collaboration with other com-
                                                                 biotech companies, are generating exciting therapies for         panies that complement our core competencies. Forming
   Even before the COVID-19 pandemic, Rentschler Bio-            the future along with excellent employment opportuni-            technology alliances and integrating the skills of other
   pharma and Vetter, both headquartered in the heart of         ties for skilled professionals. Another decisive factor is a     specialists into our business processes is an important
   Baden-Wuerttemberg, foresaw the need to accelerate the        good mix of auditors, lawyers, architects and engineers          part of our global strategy.
   production of new therapeutics. Our two companies took        with experience and expertise in this sector and the ac-
   action and entered into a strategic collaboration, aimed      tive presence of BIOPRO Baden-Wuerttemberg GmbH.                 Both Rentschler Biopharma and Vetter are committed to
   at reducing complexity along the biopharmaceutical value      The Baden-Wuerttemberg region is very well positioned            long-term and sustainable value creation. It is part of our
   chain. The desired goal of the collaboration is to support    to promote an environment for highly specialized biop-           culture to see clients as partners and to see our services as
   our clients by aligning manufacturing approaches - from       harmaceutical manufacturing in the heart of Europe.              an extension of our clients’ activities. We consult our cli-
   the first steps in biopharmaceutical drug production to                                                                        ents right from the early stages of new drug development
   the aseptic filling and packaging for market distribution.    Joining forces                                                   and enter into strategic alliances to ensure the best offer-
   Both our companies have a long history of success in our      The COVID-19 pandemic has underlined the urgent                  ings and processes for our clients. This flexibility enables
   respective fields. We are now leveraging this experience to   need to reduce drug manufacturing time. This requires            us to adapt optimally to the needs of the market.
   create long-term added value for our clients by optimizing    even closer coordination between Rentschler Biopharma’s
   process development, product manufacturing and supply         manufacturing of complex drug substances, and Vetter’s           Last year, nobody would have imagined that the world
   chains, that enable our clients to bring their products to    aseptic filling and packaging of drugs. The basis of our         today would face unprecedented challenges due to the               Information and contact
   patients more easily and faster.                              collaborative work will therefore be the development of          COVID-19 pandemic. Companies must be open to col-                  Rentschler Biopharma SE
                                                                 new complementary processes from these two areas of bi-          laboration if they are to emerge unscathed or indeed               E-Mail:
   An important hub                                              opharmaceutical contract manufacturing, that will in turn        stronger from these very different conditions and be able    
   Over the past decades, Vetter and Rentschler Biopharma,       accelerate the overall process.                                  to meet the needs of doctors and patients. Beyond this,
   both of which are family-run companies, have maintained                                                                        regional cooperation can also contribute to a dynamic, ro-         Vetter Pharma-Fertigung GmbH & Co. KG
   a good relationship based on mutual respect. We often         By combining our strengths in a strategic collaboration,         bust environment for the biotech sector in Baden-Wuert-            E-Mail:
   work with the same clients, albeit on different aspects of    we can offer clients a manufacturing chain with opti-            temberg.                                                     

30 | Healthcare industry 2020                                                                                                                                                                                                    Healthcare industry 2020 | 31
Research in Baden-Württemberg                                                                                                                                                             Prof. Dr. Oliver G. Opitz,
                                                                                                                                                                                  Head of the Coordination Center for
                                                                                                                                                                                   Telemedicine Baden-Württemberg

                                                                                                                                 Translation in Medicine
   The Healthcare Industry in Baden-Württemberg is en-              lishing NCT-Südwest in September 2020, as part of the        Unfortunately, the terms innovation and translation are          “sandbox” implementation in the form of living labs and
   riched by a diverse and effective academic research              German Federal Ministry of Education and Research’s          often misused, not only in medicine. Innovation de-              testbeds is needed. The cost-benefit assessment is often
   landscape. Healthcare research is carried out at eight                                                18
                                                                    National Decade against Cancer . Baden-Württemberg is        scribes the placement of new technologies on the mar-            completely overlooked. Why, for example, should a hos-
   universities, 15 universities of applied sciences, 21            represented in the German Consortium for Translation-        ket, thus rendering them available to the general public.        pital CEO make advance payments for investment costs
   non-university research institutions and five university         al Cancer Research (DKTK) in three ways: by the focus        Too often, however, innovation is used to describe ei-           that will only allow him to make savings through new
   hospitals. Baden-Württemberg is also well positioned in          on cancer immunotherapy in Tübingen, the epigenetics         ther ideation (the generation of ideas) or testing. The          (digital) processes years later? This is why many innova-
   the field of top-level translational - patient-related - re-     expertise in Freiburg and the German Cancer Research         same applies to translation, the process of implementa-          tions - or rather ideas - from academia and start-ups in
   search. In addition to the National Centre for Tumour            Center (DKFZ) in Heidelberg. The aim of the DKTK             tion starting from ideation. However, many - if not most         the healthcare sector are difficult to “sell”. And yet, the
   Diseases (NCT) in Heidelberg, a consortium of the Uni-           is to strengthen translational cancer research in the long   - new ideas never go beyond the pilot phase to reach             healthcare sector is currently facing immense challenges:
   versity Hospitals in Ulm and Tübingen and the Robert             term.                                                        the open market, i.e. the healthcare system. The term            shortage of expert medical staff is an increasing problem,
   Bosch Hospital in Stuttgart was granted funds for estab-                                                                      translation is therefore often used for preliminary stages       the demographic change is exacerbating the problem for
                                                                                                                                 such as minimally viable products or clinical trials. The        both healthcare providers and patients, and the num-
                                                                                                                                 indicator should rather be the sustainable rate of pilot         ber of complex chronic conditions is constantly raising,
                                                                     Mannheim                                                    projects that make it into the market.                           making medical treatment more expensive. Here, trans-
        University                                                                                                                                                                                lational catalysts can help to overcome barriers and gaps
        University of Applied Sciences                                                                                           The translation process - in the sense of implementation         to improve the efficiency of the value chain. This means
        University Hospital                                                                                                      - consists of at least four essential steps of a translational   promoting new processes and health care solutions using
        Non-university research institution                                                                                      value chain: (1) demand, (2) novelty value, (3) stakehold-       digitization in the healthcare system, explicitly from pre-
                                                                                                                                 er involvement and (4) cost-benefit assessment. But why          vention and healthcare in the regional context to special-
                                                                      Pforzheim                                                  do so few health innovations reach the public? Why are           ised applications in academic medicine.
                                                                                                                                 they so rarely implemented on the market? In most cases,
                                                                                   Stuttgart                      Aalen          the value chain breaks off too early and is not geared to
                                                                                             Denkendorf                          needs. The implementation process is complex, various
                                                                                               Nürtingen                         stakeholders are involved and the framework constantly
                                                                                 Tübingen                                        changes. The healthcare market is not a standard mar-
                                                                                            Reutlingen          Ulm
                                              Offenburg                                                                          ket, and innovations that would introduce system-wide
                                                                            Albstadt-                                            time- and cost savings are difficult to implement, as costs
                                                                                                                                 and benefits do not occur at the same time or the same
                                                                                                                                 place. In addition, stakeholders as framework conditions
                                             Furtwangen           Villingen-                                                     are changing with increased digitization.
                                      Freiburg                    Schwenningen                       Biberach

                                                                                                                                 Steps (3) and (4) are often considered too late, too lit-          Information and contact
                                                                                                                                 tle or not at all, despite being critical to success. Stake-       Telemedicine Coordination Office Baden-Württemberg
                                                                            Konstanz             Weingarten                      holder involvement often works on a random basis or is             E-mail:
                                                                                                                                 based on existing cooperations. Here a flexible and open      

32 | Healthcare industry 2020                                                                                                                                                                                                     Healthcare industry 2020 | 33
You can also read